177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
Neuroblastoma is a rare childhood cancer that develops in nerve cells. When it comes back (relapses) or does not respond to initial treatment (refractory), finding effective new options is vital. The LuDO-N trial is testing a targeted radioactive medicine called 177Lu-DOTATATE in children aged 18 months and older. The medicine works like a guided missile: it latches onto specific markers on neuroblastoma cells and delivers radiation directly into the tumour, aiming to limit harm to healthy body parts. Children receive two doses across a two-week period. Because radiation can lower healthy blood cell counts, children have some of their own stem cells collected and frozen in advance to help their bone marrow recover if needed. Doctors will track how tumours respond one and four months after treatment, while closely checking for side effects.
At a glance
What is this study about?
Neuroblastoma is a rare cancer that mostly affects babies and young children, growing from nerve tissue often found in the tummy or around the spine. While many children respond well to standard treatments like chemotherapy and surgery, 'high-risk' neuroblastoma can sometimes resist treatment or return after finishing therapy. When this happens, doctors look for innovative ways to attack the cancer cells.
The LuDO-N trial is studying a targeted therapy called 177Lu-DOTATATE. Many neuroblastoma cells have tiny docking points on their surface called somatostatin receptors. The trial medicine attaches to these docking points and releases a small dose of radiation straight into the cancer cell to destroy it from within, sparing as much healthy tissue as possible.
This study builds on earlier research by testing an 'intensified' plan: giving two doses close together over two weeks. Doctors hope this faster delivery gives the rapidly growing cancer less time to recover. Because radiation can temporarily affect the bone marrow where blood cells are made, every child has their own stem cells collected beforehand as a safety measure, ready to be returned if blood counts need a boost.
The main goal is to see how well tumours shrink at one and four months following the treatment. Researchers also want to measure how safe the treatment is, manage any side effects, and find out whether special scans can predict which children will benefit most.
Key takeaways
- Tests an intensified two-dose schedule of targeted radiation therapy over two weeks.
- Aimed at children aged 18 months and older with relapsed or hard-to-treat neuroblastoma.
- Requires a special scan first to prove the tumours can take up the medicine.
- Stored stem cells are kept ready as a safety net to help blood cells recover if needed.
- Participation is completely optional, and you can withdraw at any point.
Who may be eligible?
This study is open to children aged 18 months and older who have been diagnosed with high-risk neuroblastoma that has either returned after treatment or did not respond to standard initial therapies.
To take part, children need a special type of scan (called a DOTATATE PET scan) showing that their tumours absorb the trial medicine. They must also have enough energy for daily activities (a performance score above 50%), reasonable kidney and liver function, and satisfactory blood counts. In addition, their medical team must have already collected and stored enough of the child's own blood stem cells to use for a transplant if necessary.
Children cannot take part if they have had other cancer treatments within the past two weeks without fully recovering, if they have not recovered from recent major surgery, or if their general health is too poor to safely undergo the therapy.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- The child is at least 18 months old.
- The child has high-risk neuroblastoma that has returned or not responded to treatment.
- A recent DOTATATE scan shows good uptake in the tumour.
- The child has had at least a two-week break from previous cancer treatments.
- Healthy blood stem cells have been collected and stored for backup.
- Liver, kidney, and blood tests meet the trial safety requirements.
What does participation involve?
If your child joins the trial, they will first have screening tests, including blood checks and special scans (such as PET, CT, or MRI) to ensure the treatment is suitable for them. Treatment involves receiving two doses of 177Lu-DOTATATE through a drip into a vein, given about two weeks apart.
Because the medicine is radioactive, your child will stay in a specialised hospital room for a few days after each dose until radiation levels fall to a safe level for them to go home. Hospital staff will guide you on how you can safely stay with and care for your child during this time. Blood tests will be done regularly to check how their bone marrow is recovering; if blood counts remain very low, their stored stem cells will be given back to help them bounce back. Your child will return for follow-up scans at one month and four months after treatment, followed by ongoing routine health checks to monitor their progress.
Potential risks and benefits
Locations (9)
- RigshospitaletVerified postcodeCopenhagen, Denmark· Recruiting
- Vilnius University HospitalVerified postcodeVilnius, Lithuania· Recruiting
- Princess Maxima Center for Pediatric OncologyVerified postcodeUtrecht, Netherlands· Recruiting
- Oslo University Hospital, RikshospitaletVerified postcodeOslo, Norway· Recruiting
- Pediatric Cancer Center Barcelona, Sant Joan de Déu Barcelona Children's HospitalVerified postcodeBarcelona, Spain· Recruiting
- Karolinska University HospitalVerified postcodeStockholm, Sweden· Recruiting
- GREATER GLASGOW HEALTH BOARD, Royal Hospital for ChildrenVerified postcodeGlasgow, United Kingdom· Recruiting
- University College London Hospitals NHS FOUNDATION TRUSTVerified postcodeLondon, United Kingdom· Recruiting
- The Royal Marsden NHS Foundation Trust of Fulham RoadVerified postcodeLondon, United Kingdom· Recruiting
Common questions
How does 177Lu-DOTATATE target cancer cells?
It combines a carrier molecule that seeks out specific targets on neuroblastoma cells with a small radioactive particle. Once locked onto the tumour cell, it delivers radiation directly to it to cause damage.
Will my child be radioactive after receiving the medicine?
Yes, for a short period. Your child will stay in a specially prepared hospital room for a few days until radiation monitors show it is safe for them to leave and be around others.
Can parents stay in the room with their child?
Yes, parents are usually able to stay, but the hospital team will provide simple safety rules, such as spending time at a slight distance and limiting visits from pregnant women or other children.
Why do stem cells need to be collected beforehand?
Radiation can weaken the bone marrow, which makes blood cells. Having your child's own healthy stem cells frozen in advance acts as a backup plan to help restart their blood production if it takes too long to recover.
What happens if my child cannot finish both doses?
Your doctors will carefully monitor your child's health. If any severe side effects occur, the medical team will pause or stop the treatment and switch to the best supportive care available.
How to find out more
Jakob Stenman, MD PhD
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.